How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,806 results for

Travel Immunization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Vaccine-preventable diseases and immunisation: Core competencies

the basic of dynamics of vaccine- preventable diseases in the population. 1.3.3 Be familiar with the concept of control, elimination and eradication. 1.3.4 Understand the principles and benefit of immunisation. 1.3.5 Describe the effect of vaccination to the community as whole (herd immunity). 1.3.6 Be familiar with the immunisation needs of special risk groups in the population (travellers, migrants, vulnerable population, immunocompromised host, healthcare worker, high risk population for underlying (...) -preventable diseases and immunisation – core competencies TECHNICAL REPORT 2 Background The European Centre for Disease Prevention and Control (ECDC) is a European Union (EU) agency with a mandate to ‘enhance the capacity of the scientific expertise in the Member States with regard to the prevention and control of communicable diseases, epidemiological surveillance and training programmes and to foster the exchange of best practices and experience with regard to vaccination programmes’ (Regulation (EC

2017 European Centre for Disease Prevention and Control - Technical Guidance

2. Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older

those at risk of disease during travel. For most people, the balance between the benefits and possible side effects of the vaccine remains overwhelmingly favourable. However, because the vaccine contains a live, weakened strain of the yellow fever virus, strict adherence to contraindications and precautions is essential to reduce the risk of serious side effects in those who may have a weaker immune system. Revaccination is generally not recommended as the duration of protection following (...) be advised to seek emergency medical attention if they develop signs or symptoms of very rare neurotropic disease (YEL-AND) or viscerotropic disease (YEL-AVD) and should receive the manufacturer’s as part of the travel consultation Yellow fever vaccine Yellow fever is a life-threatening viral infection and protective measures against the disease are essential for anyone travelling to an area where there is a risk of infection. Yellow fever vaccine ( ) is highly effective and is the best way to protect

2019 MHRA Drug Safety Update

3. Vaccine-preventable Infections and Immunization in Multiple Sclerosis

to Poser 11 or McDonald 12 criteria. Initially, the panel included only cases of MS diagnosed by a neurologist but later revised this requirement because many studies used computerized databases. Accepted control group criteria varied by question. For questions referencing the general population, studies with only neurologic disease control groups were excluded. 11 The panel included immunizations recommended by the US Centers for Disease Control and Prevention (CDC) 13 and vaccines suggested (...) and recommendations.” 1 Since then, several major studies have investigated the effects of infections and immunizations on the course of multiple sclerosis (MS). Furthermore, medicine has seen the development and approval of new vaccines and new disease-modifying therapies (DMTs) with novel mechanisms of action. The influence of these newer immunosuppressive or immunomodulating (ISIM) therapies on the efficacy of immunization has not been systematically evaluated. This guideline updates the evidence from

2019 American Academy of Neurology

4. Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2017-2018

on Immunization Practices (US) AEFI Adverse event following immunization AMMI Association of Medical Microbiology and Infectious Disease aOR Adjusted odds ratio ATIV Adjuvanted trivalent inactivated influenza vaccine BMI Body mass index CAEFISS Canadian Adverse Events Following Immunization Surveillance System CBER Centre for Biologics Evaluation and Research CCDR Canada Communicable Disease Report CDC Centers for Disease Control and Prevention CHMP Committee for Medicinal Products for Human Use CI Confidence (...) [confidence interval]: 1.05 to 2.36) to 19.11 (Intensive care unit [ICU] admission; 95% CI: 3.92 to 93.22) and 22.2 (hospitalization; 95% CI: 2.6 to 186.0) (39-41) . The conditions identified as risk factors in the studies reviewed include neuromuscular, neurovascular, neurodegenerative, neurodevelopmental conditions and seizure disorders. International bodies including the Centers for Disease Control and Prevention (CDC) (United States) (42) , the Joint Committee on Vaccination and Immunisation (United

2017 CPG Infobase

5. UNderstanding uptake of Immunisations in TravellIng aNd Gypsy communities (UNITING): a qualitative interview study Full Text available with Trip Pro

UNderstanding uptake of Immunisations in TravellIng aNd Gypsy communities (UNITING): a qualitative interview study UnderstaNding uptake of Immunisations in TravellIng aNd Gypsy communities (UNITING) A qualitative interview study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Barriers, facilitators and possible interventions around immunization uptake in Traveller and Gypsy communities were identified and prioritised. {{author}} {{($index , , , , , , , , , , , , , , , & . Cath Jackson 1, * , Lisa Dyson 2 , Helen Bedford 3 , Francine M Cheater 4 , Louise Condon 5 , Annie Crocker 6 , Carol Emslie 7 , Lana Ireland 7 , Philippa Kemsley 3 , Susan Kerr 7

2016 NIHR HTA programme

6. Completion of multiple-dose travel vaccine series and the availability of pharmacist immunizers: A retrospective analysis of administrative data in Alberta, Canada. Full Text available with Trip Pro

Completion of multiple-dose travel vaccine series and the availability of pharmacist immunizers: A retrospective analysis of administrative data in Alberta, Canada. Pharmacists in a number of countries are being trained in the administration of injections with the aim of improving access and adherence to vaccinations. However, little is known about population-level adherence to multiple-dose travel vaccines, and whether the availability of pharmacist immunizers is associated with adherence (...) to ensure adherence among travellers. Strategies to develop or improve patient and clinician reminder systems in pharmacies for travel vaccines should therefore be explored.

2019 PLoS ONE

7. Immunisations: babies up to 13 months of age

immunisation schedule. 22 September 2015 Updated leaflet to include the MenB and flu vaccination and the latest immunisation schedule. 19 September 2014 The travel information for children has been updated. 1 August 2014 Updated to include the routine childhood immunisation schedule from September 2014. 11 June 2014 Updated glossary about the number of types of pneumococcal bacteria that the vaccine protects against. 29 July 2013 First published. Related content Collection Explore the topic Is this page (...) Immunisations: babies up to 13 months of age Immunisations: babies up to 13 months of age - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote in the General Election on 12 December

2019 Public Health England

8. Handbook on designing and implementing an immunisation information system

with an IIS use case 50 Table 5. IIS linkage in a selection of EU/EEA countries with subnational systems. 50 Table 6. IIS development in four European countries 59 TECHNICAL REPORT Designing and implementing an immunisation information system v Abbreviations AEFI Adverse events following immunisation AIRA American Immunization Registry Association API Application program interface CRVS Civil registration and vital statistics DDV Danish vaccination register ECDC European Centre for Disease Prevention (...) in Spain SKOS Simple knowledge organisation system SNOMED CT Systematized nomenclature of medicine – clinical terms SSI? Statens Serum Institute SVEVAC Swedish immunisation information systems ? SYSVAK Norwegian immunisation registry ? US CDC United States Centers for Disease Control and Prevention VIS Vaccine information systems WHO World Health Organization Designing and implementing an immunisation information system TECHNICAL REPORT vi Glossary eHealth European Commission definition: the use

2019 European Centre for Disease Prevention and Control - Technical Guidance

9. Effect of Antimalarial Drugs on the Immune Response to Intramuscular Rabies Vaccination Using a Postexposure Prophylaxis Regimen Full Text available with Trip Pro

antibody levels were achieved for all 3 antimalarials. Clinical trials registration: . Keywords: antimalarial drugs; prophylaxis; rabies; vaccination. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. Similar articles R Li et al. Hum Vaccin Immunother 11 (2), 435-42. 2015. PMID 25692350. - Randomized Controlled Trial The aim of this Phase IIIb, open-label, randomized (...) study was to demonstrate the non-inferiority of immune responses and to assess the safety of a purified chick-embryo ce … P Wongsaroj et al. Vaccine 31 (13), 1748-51. 2013. PMID 23370149. - Randomized Controlled Trial Pre-exposure prophylaxis is recommended for people who will be exposed to rabies virus in the laboratory or who will contact with mammals. World Health Organization recom … SE Manning et al. MMWR Recomm Rep 57 (RR-3), 1-28. 2008. PMID 18496505. These recommendations of the Advisory

2020 EvidenceUpdates

10. A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study

specific targeted disease. The underlying immunological mechanisms responsible for these effects are incompletely understood, but evidence is mounting that the innate immune system is central to these observed effects. This study is a randomised controlled trial designed to determine the influence of two commonly administered neonatal immunisations, BCG and Hepatitis B vaccine, given at birth, on the neonatal immune responses to non-specific antigens. The investigators will recruit 200 newborns (...) is of global concern. Childhood disease-specific immunisation is irrefutably linked to the decline in deaths from these targeted infections over the last century. However, neonatal immunisation is limited, in part, by the impaired adaptive immune function in this age group. There is now an expanding body of evidence for heterologous ('non-specific') effects of various vaccines used in childhood. This refers to the immunomodulatory capabilities of vaccines to influence immune outcomes beyond the vaccine's

2015 Clinical Trials

11. Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆. Full Text available with Trip Pro

Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆. : Due to their antigenic similarities, there is a potential for immunological interaction between tetanus/diphtheria-containing vaccines and carrier proteins presented on conjugate vaccines. The interaction could, unpredictably, result in either (...) enhancement or suppression of the immune response to conjugate vaccines if they are injected soon after or concurrently with diphtheria or tetanus toxoid. We examined this interaction among adult Australian travellers before attending the Hajj pilgrimage of 2015.We randomly assigned each participant to one of three vaccination schedules. Group A received tetanus, diphtheria and acellular pertussis vaccine (Tdap) 3-4 weeks before receiving CRM197-conjugated 13-valent pneumococcal vaccine (PCV13

2017 Journal of Travel Medicine Controlled trial quality: uncertain

12. UNderstanding uptake of Immunisations in TravellIng aNd Gypsy communities (UNITING): a qualitative interview study

described similar barriers and facilitators. There was widespread acceptance of childhood and adult immunisation, with current parents perceived as more positive than their elders. A minority of English-speaking Travellers worried about multiple/combined childhood vaccines, adult flu and whooping cough. Cultural concerns about vaccines offered during pregnancy and about human papillomavirus were most evident in the Bristol English Gypsy/Irish Traveller community. Language, literacy, discrimination, poor (...) ; and (5) protected funding for health visitors specialising in Traveller health, including immunisation Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Immunization; Qualitative Research; Roma Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059

2016 Health Technology Assessment (HTA) Database.

13. Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016

asthma ; children and adolescents <18 years of age who are receiving aspirin or aspirin-containing therapy; pregnant women; and persons with immune compromising conditions, due to underlying disease, therapy, or both. LAIV, TIV or QIV can be used in children with chronic health conditions, including asthma that is not severe and cystic fibrosis without immune suppression. Adults 18 to 59 years of age TIV QIV LAIV Any of these three vaccines may be used, unless contraindicated, for healthy adults (...) Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016 NACI Statement: Seasonal Influenza Vaccine: 2015–2016 - Canada.ca Language selection Search Search Canada.ca Search Menu Main Menu You are here: NACI Statement: Seasonal Influenza Vaccine: 2015–2016 Published by: Issue: Date published: October 1, 2015 ISSN: 1481-8531 Submit a manuscript About CCDR Browse Volume 41-10, October 1, 2015: Vaccines Advisory Committee Statement

2015 CPG Infobase

14. S typhi Vi Capsular Polysaccharide Vaccine-Induced Humoral Immunity in Travelers with Immunosuppressive Therapy for Rheumatoid Disease. (Abstract)

S typhi Vi Capsular Polysaccharide Vaccine-Induced Humoral Immunity in Travelers with Immunosuppressive Therapy for Rheumatoid Disease. Typhoid fever is a global health problem, causing significant morbidity and mortality. Currently, the most widely used vaccine is the typhoid Vi capsular polysaccharide (Vi-PS) vaccine. While epidemiological studies on its efficacy have been performed in children in endemic countries, there are no efficacy studies evaluating its use in travel medicine. Response (...) to vaccination may differ in travellers receiving immunosuppressive therapy. This study investigates the humoral response to Vi-PS vaccination in travellers receiving immunosuppressive therapy for rheumatoid disease.We recruited patients from the LUMC rheumatology outpatient clinic and travellers from the travel clinic who had previously received Vi-PS vaccination and also immunosuppressive therapy for rheumatoid disease. We analysed blood samples acquired from 42 patients over a period of 3 years. We

2018 Journal of Travel Medicine

15. Sending patient reminders improves immunisation uptake

who cannot have immunisations for health reasons are protected because of the high level of immunity in the population which stops unimmunised people from coming into contact with infections. This is known as herd immunity. If the level of immunisation drops, then diseases can spread among unimmunised individuals. In 2016-17, 93.4% of children completed the three-course immunisation for diphtheria, tetanus, pertussis, polio and haemophilus influenzae type B before their first birthday. 91.6 (...) have immunisations for health reasons are protected because of the high level of immunity in the population which stops unimmunised people from coming into contact with infections. This is known as herd immunity. If the level of immunisation drops, then diseases can spread among unimmunised individuals. In 2016-17, 93.4% of children completed the three-course immunisation for diphtheria, tetanus, pertussis, polio and haemophilus influenzae type B before their first birthday. 91.6% received

2019 NIHR Dissemination Centre

16. Pre-school vaccinations: guide to vaccinations from 2 to 5 years

at this age? The pre-school immunisations – often called pre-school boosters – will update or top up your child’s level of antibodies (which their bodies produce to fight off disease and infection) and help to keep them protected. Protection (immunity) against diphtheria, tetanus, whooping cough and polio from the immunisations given to babies can fade over time. Sometimes, complete immunity to measles, mumps or rubella does not develop after a single dose of the MMR vaccine – so this gives them a second (...) of MMR vaccine. For a checklist of the vaccines and the ages at which they should ideally be given visit www.nhs.uk/vaccinations3 Contents Introduction 4 Common questions about pre-school immunisations 6 Immunisations for pre-school children 13 Flu vaccine 13 dTaP/IPV or DTaP/IPV vaccine 16 MMR vaccine 18 Watch out for meningitis and septicaemia 22 Travel advice for children 25 Routine childhood immunisation programme – a quick reference guide to your child’s immunisations 264 Pre-school

2019 Public Health England

17. Health Care Support Workers Administering Inactivated Influenza, Shingles and Pneumococcal Vaccines for Adults and Live Attenuated Influenza Vaccine (LAIV) for Children

in immunisation is maintained. The RCN only supports HCSWs to administer those vaccines listed above. The RCN does NOT support HCSWs to administer other vaccines, such as the remainder of the childhood vaccination programme or travel vaccinations. IntroductionROYAL COLLEGE OF NURSING 5 The RCN considers that, in the absence of any mandatory regulation of HCSWs, it is important to clearly define the role and boundaries of the support workforce. Training and experience In England and Wales, the National Minimum (...) outlined here may provide immunisers with some useful guidance. Northern Ireland The Public Health Agency Northern Ireland currently does not endorse HCSWs giving vaccinations and the National Minimum Standards and core curriculum for immunisation training of health care support workers (PHE, 2015) have not been endorsed. It is acknowledged however, that general practitioners, as independent practitioners, can decide how to use their staff, so this may provide them with some useful guidance

2019 Royal College of Nursing

18. The optimal age to vaccinate with the conjugate meningococcal ACWY vaccine is between 12 and 15 years

to be significantly higher for the 15-years group. As for IgG subclasses, the trends were very similar to those observed for IgG. Conclusion: the MenACWY vaccine induces robust immune responses up to 1 year after vaccination. The response was weaker in children vaccinated at age 10 years. To ensure individual protection as well as herd immunity, the authors recommend vaccination at age 12 years to protect against the rapid increase of MenW disease. Conflicts of interest: one of the authors disclosed having (...) appraised articles Van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: optimal age for vaccination. Reviewers: Ortega Páez E 1 , Esparza Olcina MJ 2 . 1 UGC Maracena. Distrito Granada-Metropolitano. Granada. España. 2 CS Barcelona. Móstoles. Madrid. España. Correspondence: Eduardo Ortega Páez. Email: Reception date: 30/11/2017

2018 Evidencias en Pediatría

19. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand

Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand Muangchana C, Riewpaiboon A, Jiamsiri S, Thamapornpilas P, Warinsatian P Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of incorporating rotavirus vaccination into a national immunisation programme. The study was requested by the Thai National Vaccine Committee. The authors concluded that rotavirus vaccination

2013 NHS Economic Evaluation Database.

20. Immune Response to Hepatitis B Vaccination: A Review of the Clinical Evidence

: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Immune Response to Hepatitis B Vaccination: A Review of the Clinical Evidence DATE: 28 March 2012 CONTEXT AND POLICY ISSUES There are three vaccines against hepatitis B virus (HBV) licensed for adult use in Canada: Engerix-B, Recombivax HB, and Twinrix (...) response to hepatitis B virus? 2. What are the evidence-based guidelines for hepatitis B vaccination of non-responders? KEY MESSAGE Evidence from randomized controlled trials and non-randomized studies indicates that the combined hepatitis A/hepatitis B (HAV/HBV) vaccine may be more effective than the HBV vaccine for generating an immune response to hepatitis B virus, however the data are not conclusive. No evidence-based guidelines recommending the use of HAV/HBV vaccine in non- responders to HBV

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>